SG Americas Securities
CORT icon

SG Americas Securities’s Corcept Therapeutics CORT Stock Holding History

SG Americas Securities’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Sell
11,706
-1,877
-14% -$113K ﹤0.01% 1872
2026
Q1 		$548K Sell
13,583
-245
-2% -$9.16K ﹤0.01% 2132
2025
Q4 		$481K Buy
13,828
+4,565
+49% +$359K ﹤0.01% 2522
2025
Q3 		$770K Buy
9,263
+6,473
+232% +$468K ﹤0.01% 1711
2025
Q2 		$205K Sell
2,790
-40,319
-94% -$2.92M ﹤0.01% 2247
2025
Q1 		$4.92M Buy
43,109
+31,922
+285% +$1.94M 0.02% 474
2024
Q4 		$564K Sell
11,187
-18,476
-62% -$968K ﹤0.01% 1218
2024
Q3 		$1.37M Buy
29,663
+21,479
+262% +$763K 0.01% 855
2024
Q2 		$266K Buy
8,184
+1,353
+20% +$37.1K ﹤0.01% 2028
2024
Q1 		$172K Sell
6,831
-206,979
-97% -$4.89M ﹤0.01% 2092
2023
Q4 		$6.95M Buy
213,810
+32,185
+18% +$884K 0.06% 274
2023
Q3 		$4.95M Buy
181,625
+83,149
+84% +$2.41M 0.06% 295
2023
Q2 		$2.19M Sell
98,476
-85,620
-47% -$1.97M 0.02% 701
2023
Q1 		$3.99M Buy
184,096
+170,491
+1,253% +$3.74M 0.05% 355
2022
Q4 		$276K Buy
13,605
+13
+0.1% +$326 ﹤0.01% 1987
2022
Q3 		$348K Sell
13,592
-22,921
-63% -$613K ﹤0.01% 1866
2022
Q2 		$868K Sell
36,513
-679,670
-95% -$14.8M 0.01% 1425
2022
Q1 		$16.1M Buy
716,183
+428,323
+149% +$9.11M 0.12% 142
2021
Q4 		$5.7M Buy
287,860
+199,095
+224% +$4.04M 0.03% 434
2021
Q3 		$1.75M Buy
88,765
+83,762
+1,674% +$1.75M 0.01% 1398
2021
Q2 		$110K Sell
5,003
-10,622
-68% -$236K ﹤0.01% 2615
2021
Q1 		$372K Sell
15,625
-103,047
-87% -$2.75M ﹤0.01% 2221
2020
Q4 		$3.1M Sell
118,672
-142,365
-55% -$3M 0.02% 804
2020
Q3 		$4.54M Buy
261,037
+7,879
+3% +$126K 0.03% 384
2020
Q2 		$4.26M Buy
253,158
+71,301
+39% +$1M 0.04% 417
2020
Q1 		$2.16M Buy
181,857
+130,018
+251% +$1.61M 0.02% 762
2019
Q4 		$627K Buy
51,839
+38,160
+279% +$531K 0.01% 1589
2019
Q3 		$193K Buy
13,679
+4,182
+44% +$51.4K ﹤0.01% 2372
2019
Q2 		$106K Sell
9,497
-2,218
-19% -$24.7K ﹤0.01% 2776
2019
Q1 		$138K Sell
11,715
-164,064
-93% -$2.04M ﹤0.01% 2838
2018
Q4 		$2.35M Buy
175,779
+168,188
+2,216% +$2.22M 0.02% 775
2018
Q3 		$106K Sell
7,591
-14,350
-65% -$201K ﹤0.01% 2848
2018
Q2 		$345K Buy
+21,941
New +$382K ﹤0.01% 2261
2017
Q3 		– Sell
-9,255
Closed -$109K – 3508
2017
Q2 		$109K Sell
9,255
-28,278
-75% -$307K ﹤0.01% 2853
2017
Q1 		$411K Buy
37,533
+16,632
+80% +$146K ﹤0.01% 1978
2016
Q4 		$152K Buy
+20,901
New +$164K ﹤0.01% 2564
2014
Q4 		– Sell
-28,419
Closed -$76K – 3177
2014
Q3 		$76K Buy
28,419
+12,316
+76% +$32.6K ﹤0.01% 2420
2014
Q2 		$45K Buy
+16,103
New +$47.5K ﹤0.01% 2411

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's CORT Position: Q2 2026 in Review

SG Americas Securities reduced its Corcept Therapeutics (CORT) stake by 14% in Q2 2026, selling an estimated $113K and leaving 11,706 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

SG Americas Securities first reported a position in CORT in Q2 2014 and has held it in 38 quarters since. The position peaked at $16.1M in Q1 2022. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • SG Americas Securities held 11,706 shares of Corcept Therapeutics worth $1.02M as of Q2 2026.
  • SG Americas Securities sold 1,877 Corcept Therapeutics shares in Q2 2026, an estimated $113K.
  • Corcept Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1872 holding.
  • SG Americas Securities first reported a position in Corcept Therapeutics in Q2 2014 and has held it in 38 quarters since.
  • SG Americas Securities's Corcept Therapeutics position peaked at $16.1M in Q1 2022.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.